Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Preferred Stock Liabilities: 2021

  • ARS Pharmaceuticals' Preferred Stock Liabilities was N/A to $54.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $54.8 million, marking a year-over-year change of. This contributed to the annual value of $54.8 million for FY2021, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Preferred Stock Liabilities of $54.8 million as of Q4 2021.
  • In the past 5 years, ARS Pharmaceuticals' Preferred Stock Liabilities ranged from a high of $54.8 million in Q4 2021 and a low of $54.8 million during Q4 2021.
  • Its 1-year average for Preferred Stock Liabilities is $54.8 million, with a median of $54.8 million in 2021.